Table 3. Psoriasis Therapy Prevalencea.
| Therapy | Number (%)b N=4,638 |
|---|---|
|
| |
| Topicalsc | 3,551 (76.6) |
| Corticosteroids | 3,477 (75.0) |
| Class I | 1,846 (39.8) |
| Non-Class I | 2,718 (58.6) |
| Calcineurin inhibitors | 121 (2.6) |
| Vitamin D analogs | 643 (13.9) |
| Retinoids | 21 (0.45) |
| Salicylic acid | 12 (0.17) |
|
| |
| Phototherapy | 324 (7.0) |
| Psoralen plus Ultraviolet A | 34 (0.73) |
|
| |
| Excimer laser | 126 (2.7) |
|
| |
| Oral systemics | 664 (14.3) |
| Methotrexate | 569 (12.3) |
| Cyclosporine | 22 (0.47) |
| Acitretin | 90 (1.9) |
|
| |
| Biologicsd | 471 (10.2) |
| Part B (physician-administered) | 146 (3.1) |
| Infliximab | 107 (2.3) |
| Ustekinumab | 37 (0.80) |
| Part D (self-injectables) | 370 (8.0) |
| Adalimumab | 161 (3.5) |
| Etanercept | 209 (4.5) |
a
Psoriasis is defined by at least two inpatient or outpatient claims for psoriasis (ICD-9-CM 696.1).
b
Percentages do not equal 100 because patients may have received more than one therapy.
c
Coal tar/anthralin use was examined but not reported separately per Centers for Medicare and Medicaid Services (CMS) data use agreement due to cell size of 10 or less.
d
Alefacept was examined but not reported separately per CMS data use agreement due to cell size of 10 or less.